SK Biopharmaceuticals Co., Ltd. (KRX:326030)

Market Cap	6.89T -26.4%
Revenue (ttm)	861.34B +38.9%
Net Income	400.96B +56.6%
EPS	5,119.90 +56.6%
Shares Out	78.31M
PE Ratio	17.19
Forward PE	18.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	148,739
Open	88,000
Previous Close	87,600
Day's Range	87,600 - 91,500
52-Week Range	67,800 - 144,100
Beta	0.66
Analysts	Buy
Price Target	131,230.77 (+49.13%)
Est. Earnings	Feb 3, 2027

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilep...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 246
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 326030

Financial Performance

In 2025, SK Biopharmaceuticals's revenue was 706.74 billion, an increase of 29.06% compared to the previous year's 547.60 billion. Earnings were 266.95 billion, an increase of 10.89%.

Analyst Summary

According to 13 analysts, the average rating for 326030 stock is "Buy." The 12-month stock price target is ₩131,231, which is an increase of 49.13% from the latest price.

Price Target

₩131,231

(49.13% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error